Intercept Pharmaceuticals, United States
Intercept Pharmaceuticals, Inc. (Employment)
OP-7A - Impact of Non-alcoholic Steatohepatitis (NASH) Case Definition on Population Characteristics Identified in a US Claims Database
Wednesday, August 25, 202111:45 AM – 1:30 PM US Eastern Time
OP-7F - Incidence Rates of Select Outcomes Among Patients with Non-alcoholic Steatohepatitis (NASH) and Evidence of Fibrosis and Cirrhosis